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Edited by Laszlo NagyAbstract Cytosolic phospholipase A2a (cPLA2a) plays an
important role in arachidonate pathway. To investigate the con-
tribution of cPLA2a to autoimmune diabetes, we established
non-obese diabetic (NOD) mouse, an excellent model for human
type 1 diabetes, deﬁcient in cPLA2a. These mice showed severe
insulitis and a higher incidence of diabetes. In their macrophages,
decreased prostaglandin E2 (PGE2) induced by cPLA2a deﬁ-
ciency, and the increase in production of tumor necrosis factor
(TNF)-a were observed. These results suggested that cPLA2a
plays a protective role in progression of insulitis and development
of autoimmune diabetes by suppression of TNF-a production
from macrophages.
 2005 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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The non-obese diabetic (NOD) mouse, an excellent model for
human type 1 diabetes, spontaneously develops autoimmune
diabetes [1,2]. In this model, insulitis is caused by the inﬁltration
of macrophages as well as CD4+ and CD8+ T cells [3], and the
presence of cytokines such as tumor necrosis factor (TNF)-a
in the insulitis lesion is implicated in the development of diabetes
[4]. It is also well known that macrophage plays a crucial role in
the progression of insulitis and development of diabetes.
Arachidonic acid is liberated from membrane phospholipids
mainly by phospholipase A2s (PLA2s). Macrophages contain
at least three diﬀerent PLA2s: i.e., a cytosolic phospholipase
A2a (cPLA2a) and a secretory PLA2 (sPLA2), both of which
require Ca2+ ion, and a Ca2+ ion-independent PLA2 (iPLA2)
[5,6]. Several studies have demonstrated that some cPLA2a-
mediated eicosanoids are involved in the immune system [6].Abbreviations: APC, antigen-presenting cell; cPLA2a, cytosolic phos-
pholipase A2a; FBS, fetal bovine serum; NO, nitric oxide; NOD, non-
obese diabetic; PGE2, prostaglandin E2; ROS, reactive oxygen species;
TNF, tumor necrosis factor
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doi:10.1016/j.febslet.2005.06.024In particular, prostaglandin E2 (PGE2), a cyclooxygenase
(COX) product of cPLA2a-mediated arachidonic acid, is a
major eicosanoid released by antigen-presenting cells (APCs).
Therefore, it can be expected that cPLA2a-mediated eicosa-
noids play signiﬁcant roles in autoimmune diseases, including
type 1 diabetes. Previously, we have established cPLA2a
knockout mice that showed a marked decrease in the produc-
tion of eicosanoids by their peritoneal macrophages [7]. In this
study, we established cPLA2a knockout NOD mice to investi-
gate the role of cPLA2a in the autoimmune responses during
the development of diabetes.2. Materials and methods
2.1. Mice
cPLA2a knockout NOD mice were obtained by crossing cPLA2a
knockout C57BL/6 mice [7] with NOD mice (CLEA Japan, Tokyo, Ja-
pan). In the N6 generation, the male that was the most enriched for
NOD-type microsatellite markers was selected by the speed congenic
approach as described elsewhere [8]. We found a male mouse in that
generation that had NOD-type microsatellite markers in all its chro-
mosomes, and it was used to produce the next generation. The
cPLA2a
+/ (heterozygous knockout) NOD mice in the N11 generation
were then intercrossed to generate cPLA2a
+/+ (wild-type), cPLA2a
+/,
and cPLA2a
/ (homozygous knockout) female NOD mice. Mice were
kept under speciﬁc pathogen-free conditions in the animal facility of
Osaka University Graduate School of Medicine. Urinary glucose anal-
ysis was performed using Tes-tape (Eli Lilly, Indianapolis, IN) weekly
starting at 10 weeks of age. Plasma glucose levels were determined
using Glutest-Ace (Sanwa Kagaku, Nagoya, Japan) when glucosuria
was detected, and mice were considered to be diabetic after two consec-
utive examinations of blood glucose values >250 mg/dl.
2.2. Genotype analysis by PCR
The genotype of the cPLA2a locus was determined by PCR analysis
using genomic DNA prepared from tail biopsies as the template. The
nucleotide sequences of the primers were described elsewhere [7]. The
reaction was performed using a Taq polymerase (Life Technologies,
Grand Island, NY). The PCR was performed at 94 C for 2 min,
and then 30 cycles of 94 C for 1 min, 55 C for 1 min, and 72 C for
1 min, followed by extension at 72 C for 10 min. The PCR products
were separated by electrophoresis in a 1.5% agarose gel.2.3. Histology
The pancreas was removed from each mouse, ﬁxed in 10% formalde-
hyde, and embedded in paraﬃn. Thin sections at ﬁve levels, 100 lm
apart, were cut for staining with hematoxylin-eosin to evaluate the is-
let-inﬁltrating immune cells by light microscopy. At least 25 islets from
each mouse were observed and scored by two independent blinded
observers using the following criteria: grade 0, islets free of insulitis;ation of European Biochemical Societies.
Fig. 2. Severity of insulitis in cPLA2a knockout NOD mice. Insulitis
in non-diabetic mice from each group was evaluated at 10 weeks of age
(cPLA2a
+/+, n = 5; cPLA2a
+/, n = 5; cPLA2a
/, n = 5) and at 18
weeks of age (cPLA2a
+/+, n = 7; cPLA2a
+/, n = 7; cPLA2a
/, n = 7).
*P < 0.05 (by Mann–Whitney U test). Data are shown as the
means ± SE.
3976 Y. Oikawa et al. / FEBS Letters 579 (2005) 3975–3978grade 1, islets with lymphocyte inﬁltration in <25% of the area; grade
2, lymphocyte inﬁltration in 25–50% of the area; grade 3, lymphocyte
inﬁltration in 50–75% of the area; grade 4, lymphocyte inﬁltration in
>75% of the area or small retracted islets. The histological score gives
the mean inﬁltration grade of the islets analyzed.
2.4. Cytokines and PGE2 measurement by ELISA
Mouse IL-12, mouse TNF-a, and PGE2 levels were analyzed using
a mouse IL-12 ELISA kit (Endogen, Woburn, MA), mouse TNF-a
ELISA kit (Endogen), and PGE2 ELISA kit (Amersham Biosciences,
Buckinghamshire, UK), respectively, according to the manufacturers
instructions.
2.5. Preparation and stimulation of peritoneal macrophages
The procedures were published previously [7]. Brieﬂy, peritoneal
exudate cells were harvested by injecting 10 ml of ice-cooled phos-
phate-buﬀered saline (PBS) into the peritoneal cavity. The collected
cells were transferred to each well of a ﬂat-bottom, 96-well microplate
at 3 · 105 cells/200 ll in RPMI1640 medium (Life Technologies) sup-
plemented with 10% heat-inactivated fetal bovine serum (FBS) (Life
Technologies) and penicillin/streptomycin (Life Technologies). The
adherent cells after 1 h of incubation were used as resident peritoneal
macrophages. After 18 h incubation, the medium was aspirated, re-
placed with FBS-free RPMI1640 medium containing the Ca2+ iono-
phore A23187 (5 lM; Wako Pure Chemical Industries, Osaka,
Japan) or LPS (1 lg/ml; Sigma) and incubated for 30 min or 8 h,
respectively. After the supernatants were collected, IL-12, TNF-a,
and PGE2 were quantiﬁed using the ELISA kit described above.
2.6. Statistical analysis
Results are presented as the means ± SE. The log-rank test was used
to compare the incidence of diabetes. Diﬀerences in insulitis score and
cytokine production levels were analyzed using the Mann–Whitney U
test. A value of P < 0.05 was considered statistically signiﬁcant.3. Results and discussion
As shown in Fig. 1, the cumulative incidence of diabetes was
signiﬁcantly higher in the cPLA2a
/ NOD mice than in the
cPLA2a
+/+ or cPLA2a
+/ NOD mice, although there was no
diﬀerence in the timing of the onset of diabetes among the
three groups. The mean insulitis score was signiﬁcantly higher
at 18 weeks of age (diabetic stage; i.e., just before the onset of0
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Fig. 1. Eﬀect of cPLA2a knockout on the incidence of diabetes in
NOD mice. cPLA2a
+/+ (n = 19), cPLA2a
+/ (n = 35), and cPLA2a
/
(n = 26) female NOD mice were monitored for glucosuria weekly,
starting at 10 weeks of age. *P < 0.03 vs. cPLA2a
+/+ and P < 0.01 vs.
cPLA2a
+/ (by the log-rank test).overt diabetes) in the cPLA2a
/ NOD mice than in the
cPLA2a
+/+ and cPLA2a
+/ NOD mice, although no signiﬁcant
diﬀerence in insulitis scores was observed at 10 weeks of age
(prediabetic stage) among the three groups (Fig. 2). These ﬁnd-
ings indicate that cPLA2a deﬁciency accelerates the develop-
ment of insulitis, not in the prediabetic stage, but in the
diabetic stage, leading to the acceleration of diabetes. In other
words, cPLA2a is likely to play a protective role in the acceler-
ation of insulitis in the diabetic stage.
In our previous reports, PGE2 production was signiﬁcantly
suppressed in peritoneal macrophages of cPLA2a
/ mice [7].
As the peritoneal macrophages are known to be involved in
the development of diabetes in NOD mice [9–11], we investi-
gated the production of PGE2 by the peritoneal macrophages
of cPLA2a
+/+, cPLA2a
+/, and cPLA2a
/ NOD mice at 18
weeks of age. When peritoneal macrophages were stimulated
with a Ca2+ ionophore (A23187) for 30 min or LPS for 8 h,
PGE2 production was markedly lower in the cPLA2a
/
NOD mice than in the cPLA2a
+/+ and cPLA2a
+/ NOD mice
(Fig. 3A and B).
To evaluate whether cPLA2a deﬁciency aﬀects the cytokine
proﬁle in APCs, we investigated the production of TNF-a
and IL-12, which are considered to be involved in the develop-
ment of diabetes in NOD mice, by peritoneal macrophages of
cPLA2a
+/+, cPLA2a
+/, and cPLA2a
/ NOD mice at 18
weeks of age (Fig. 4). When peritoneal macrophages were
stimulated with LPS for 8 h, TNF-a production was signiﬁ-
cantly higher in the cPLA2a
/ NOD mice than in the
cPLA2a
+/+ and cPLA2a
+/NOD mice. This result is consistent
with the report that TNF-a production from murine macro-
phages was inhibited by PGE2 [12]. On the other hand, IL-
12 production levels from peritoneal macrophages could not
be compared among the three groups (cPLA2a
+/+, cPLA2a
+/,
and cPLA2a
/ NOD mice) because all of the data were below
detection limit in our ELISA system.
Accumulating evidences proved that TNF-a has a potent ef-
fect on the development of diabetes in NOD mice. It has been
reported that TNF-a is produced in macrophages or dendritic
cells inﬁltrating in insulitis lesions [13]. Systemic administra-
tion of TNF-a to neonatal NOD mice accelerated diabetes
Fig. 3. PGE2 production from peritoneal macrophages of cPLA2a
knockout NOD mice. (A) Stimulation of peritoneal macrophages from
each group (cPLA2a
+/+, n = 3; cPLA2a
+/, n = 3; cPLA2a
/, n = 3) by
A23187 was performed at 18 weeks of age, and the PGE2 production
level was examined using ELISA. (B) Stimulation of peritoneal
macrophages from each group (cPLA2a
+/+, n = 3; cPLA2a
+/, n = 3;
cPLA2a
/, n = 3) by LPS was performed at 18 weeks of age, and the
PGE2 production level was examined using ELISA. *P < 0.05 (by
Mann–Whitney U test). Data are shown as the means ± SE.
Fig. 4. TNF-a production from peritoneal macrophages of cPLA2a
knockout NOD mice. Stimulation of peritoneal macrophages from
each group (cPLA2a
+/+, n = 3; cPLA2a
+/, n = 3; cPLA2a/, n = 3)
by LPS was performed at 18 weeks of age, and the TNF-a production
level was examined using ELISA. *P < 0.05 (by Mann–Whitney U
test). Data are shown as the means ± SE.
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into neonatal NOD mice signiﬁcantly delayed disease onset
[14]. In the transgenic mouse, overexpressing a soluble TNF-
a receptor, which neutralize the eﬀect of TNF-a, the severity
of insulitis was decreased and the development of diabetes
was completely inhibited [15]. Moreover, islet-speciﬁc TNF-a
expression in NOD mice accelerated the development of diabe-
tes [16,17]. Thus, the high TNF-a production by APCs might
evoke the acceleration of the development of insulitis and dia-
betes in our cPLA2a
/ NOD mice.
Although it has not been proven that TNF-a is directly toxic
to b-cells in vivo, TNF-a-mediated oxidative stress seems to
play an important role in the destruction of b-cell. Corbett
et al. reported that the activation of intra-islet macrophages
stimulated with a combination of TNF-a and LPS results in
intra-islet release of IL-1. Subsequently, IL-1 induces expres-
sion of inducible nitric oxide synthase (iNOS) in b-cells, lead-
ing to the production of NO in b-cells [18]. Because NO or
other reactive oxygen species (ROS) are considered to be b-cell
cytotoxic, the synergistic interaction between enhanced TNF-a
in intra-islet APCs and ROS in b-cells is possible to contribute
to acceleration of b-cell destruction in cPLA2a
/ NOD mice.
In the immune system, prostanoids are produced mainly by
APCs (macrophages and dendritic cells) and play an important
role in regulating T-cell development and function [6]. In par-
ticular, PGE2 inhibits Th1 cell development from naive T cells
[19–21]. Moreover, PGE2 suppresses IL-2 and IFN-c produc-
tion by Th1 cells, but not IL-4 and IL-5 production by Th2
cells [22,23]. Also, a recent study demonstrated that indometh-
acin- or EP4 (one of PGE2 receptor subtypes) antagonist-
treated macrophages augmented their IL-12 production via
an inhibition of PGE2 action and enhanced T cell-derived
IFN-c production after LPS-stimulation [24]. Therefore, the
accelerated Th1-type immune responses evoked by inhibition
of PGE2 production might contribute to the development of
overt diabetes, although we could not observe the signiﬁcant
change in the cytokine proﬁles in our cPLA2a
/ NOD mice,
at least for the pancreas and pancreatic lymph nodes (data
not shown). In order to clarify the association between PGE2
deﬁciency and Th1-type immune responses, further studies
using PGE2 deﬁcient NOD mice are required in the future.
In conclusion, we demonstrated here that a cPLA2a deﬁ-
ciency resulted in decreased PGE2 production by peritoneal
macrophages, leading to the increase in TNF-a production
by APCs, contributing to the acceleration of diabetes. These
ﬁndings suggest that cPLA2a is likely to play a protective role
in the pathogenesis of autoimmune diabetes.
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